4:37 PM
 | 
Sep 12, 2017
 |  BC Extra  |  Company News

Regulatory round-up: Array, Sandoz, Sorrento, Adello

FDA accepted for review a number of applications, including NDAs from Array BioPharma Inc. (NASDAQ:ARRY) and BLAs for two biosimilar candidates.

FDA assigned a June 30, 2018 PDUFA date to a pair of NDAs from Array for binimetinib (MEK162) and encorafenib (LGX818) in combination to treat BRAF-mutant advanced, unresectable or metastatic melanoma. Last month, the company said it filed two NDAs since each compound will have...

Read the full 323 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >